News Releases

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Dec. 16, 2024-- KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), today announced that Jeb Ledell has joined the Company as Chief Operating Officer (COO). Mr. Ledell is an accomplished public company COO with a track record of driving

–Continuing to build commercial infrastructure; on track for potential sebetralstat launch in Q2 2025– –Multinational regulatory submissions for sebetralstat position Company to transform hereditary angioedema (HAE)   treatment worldwide– –Pro forma cash and cash equivalents of $292.2 million

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Dec. 4, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted five newly-hired employees inducement options to purchase an aggregate of 36,000 shares of

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Nov. 26, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Laurence Reid , Ph.D., has been appointed to the Company’s Board of Directors, effective immediately. Dr. Reid brings more than three decades of experience

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Nov. 12, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at each of the following investor conferences: Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Nov. 5, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted twelve newly-hired employees inducement options to purchase an aggregate of 78,000 shares

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Nov. 4, 2024-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) (“KalVista”) today announced the pricing of an underwritten offering of 5,500,000 shares of its common stock at a price of $10.00 per share to certain investors (the “Offering”).

–Provides up to $184 million investment to support commercial launch of sebetralstat which, if approved, will be the first and only oral on-demand therapy for HAE – –Strengthens financial position as KalVista establishes global footprint for expected launches in multiple geographies in 2025–

–Phase 3 trial data show that early treatment is correlated with shorter attack duration– – Rigorous comparison of Phase 3 results for oral sebetralstat and pivotal trial results of IV recombinant C1-inhibitor for on-demand treatment of HAE attacks shows no differences in time to beginning of

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Oct. 18, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that five abstracts have been accepted for e-Poster presentation at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology